Navigation Links
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
Date:8/7/2009

LOS ANGELES, Aug. 7 /PRNewswire-USNewswire/ -- A new drug delivery system that uses a tiny silicone cup filled with any drug and sealed to the outer surface (episclera) of the eyeball may offer a more effective method for the sustained delivery of medicines for retinal and vitreous diseases, according to a new report by A. Linn Murphree, M.D, director of the Retinoblastoma Program in The Vision Center at Children's Hospital Los Angeles. Dr. Murphree is also Professor of Ophthalmology and Pediatrics at the Keck School of Medicine of the University of Southern California and attending physician at the Doheny Eye Institute.

In his invited presentation, made July 30th, 2009 at the Association for Research in Vision and Ophthalmology (ARVO) Summer Eye Research Conference on Ophthalmic Drug Delivery Systems in Bethesda, MD, Dr. Murphree said the device, called an episcleral drug reservoir, holds the potential to fundamentally change how we deliver medications to the eye for diseases like macular degeneration, diabetic retinopathy, uveitis, endophthalmitis and retinoblastoma. Working much like an organ-specific transdermal skin patch, the tiny cup isolates the medication targeted to the eye from being absorbed into the blood stream. This new delivery system is a safe and non-invasive way to deliver effective doses of medications to the interior of the eye over long periods of time (weeks to months). Currently drops, periocular injections and intraocular injections are used to deliver medications to the eye but generally for short periods of time.

Dr. Murphree, who is a recipient of a National Institutes of Health RAID grant which provides funding for the development of procedures leading to clinical trials, believes the development of this type of delivery device represents a paradigm shift in the way physicians will deliver drugs to all organ systems in the future.

"The implantation of this kind of device on any organ and the ability to deliver medication to the affected organ, could be a huge advance in how we currently treat cancer," Dr. Murphree said. This work is done in conjunction with Ricardo Carvalho, M.D., Ph.D. and the company 3T Ophthalmics which is developing the drug delivery system.

The episcleral drug reservoir is inserted under the thin, filmy conjunctiva, or covering of the eyeball, to the sclera -- the fibrous, protective outer layer of the eye. The tiny cup administers the drug slowly by passive diffusion through the sclera, where it reaches the retina and vitreous. The device is so small the patient should feel little or no discomfort and it does not hinder normal vision.

Currently, drugs for most retinal diseases are delivered either through an I.V. drip (i.e. systemically) or by an injection into the eyeball (i.e. intravitreal), both of which pose risks for the patient.

For example, chemotherapy for retinoblastoma, a cancer affecting one in 15,000 children, must now be given intravenously. This requires relatively large doses of the drug are needed to achieve a therapeutic concentration in the retina. The chemotherapy destroys the bone marrow and depresses the child's immune system, often leading to secondary infections.

Intravitreal injections using a syringe, often used to treat age-related macular degeneration, require frequent out-patient visits and can lead to vitreous hemorrhage and retinal detachment. Eye drops are also generally ineffective for retinal diseases because most medications are washed away or diluted before they have a chance to reach the retina, located at the back of the eye close to the brain.

"When we administer chemotherapy to an infant for retinoblastoma at The Vision Center, it is expensive and puts a great strain on the family, especially if they are from another state. Our preliminary research shows that once the cup is fitted, the child should be able go home for several weeks. Because the drug is being administered directly into the eye and not systemically, chemotherapy dosage levels will be much lower and the debilitating side effects will be reduced," said Dr. Murphree.

With preliminary testing complete, Dr. Murphree is currently developing a protocol for Phase I/II clinical trials in humans to take place over the coming year.

Founded in 1928 with 12,000 members currently, ARVO is one of the nation's largest organizations for research in vision and ophthalmology. For more information, see www.arvo.org.

The Vision Center at Children's Hospital Los Angeles is an international referral center known for its family friendly environment of children afflicted with all forms of eye disease and provides a full range of inpatient and outpatient services. It is the largest pediatric ophthalmology program in the nation with multiple subspecialty programs that are considered to be among today's finest resources for diagnosis, treatment and research.

Founded in 1901, Children's Hospital Los Angeles has been treating the most seriously ill and injured children in Los Angeles for more than a century, and it is acknowledged throughout the United States and around the world for its leadership in pediatric and adolescent health. Children's Hospital is one of America's premier teaching hospitals, affiliated with the Keck School of Medicine of the University of Southern California since 1932. It is a national leader in pediatric research.

For more information, see www.TheVisionCenterAtCHLA.org.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.

CONTACT: James Harris, +1-310-398-5565, jtharris5@ca.rr.com, for Children's Hospital Los Angeles; or Amanda Hedlund of The Vision Center, Children's Hospital Los Angeles, +1-323-361-7691, ahedlund@chla.usc.edu


'/>"/>
SOURCE Children's Hospital Los Angeles
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
2. Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
3. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
4. Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients
5. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
6. Back to Normal: Surgery Improves Outcomes for Spine Patients
7. New Research Shows Nutrition 21s Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings
8. New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
9. Program Improves Language Skills in Deaf, Hard of Hearing
10. Brain Training Improves Memory and Attention and the Effects Last
11. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... May 24, 2016 Los ... terapia del mundo, introduce catéteres para la intervención ... OrbusNeich, una compañía global especializada en el suministro ... expandido su cartera incluyendo productos para tratar la ... Scoreflex™ PTA son los dispositivos de primera entrada ...
(Date:5/24/2016)... -- Dutch surgeons have launched a ground-breaking medical app ... treat patients on a global scale. Medical professionals from ... and the US have already signed up for the ... a totally secure environment. Education  "Imagine a ... with a surgeon at Harvard to treat a bomb victim via ...
Breaking Medicine Technology:
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
(Date:5/26/2016)... D.C. (PRWEB) , ... May 26, 2016 , ... On ... men and women who lost their lives in military battle for the country. ... cards in 2015 to provide more programs that empower independence for disabled military veterans, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced two key appointments and the ... investment and strategic growth plans in the Asia Pacific region. , Howard Kim ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon ... officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International ... May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on ...
Breaking Medicine News(10 mins):